Thermo Fisher Scientific to acquire Qiagen

3 Mar 2020

Thermo Fisher Scientific said Tuesday it has agreed to buy Dutch molecular testing and diagnostics specialist Qiagen for €39 per share in cash, valuing the overall transaction at around USD 11.5 billion.

According to Thermo, the acquisition will bring together the companies’ complementary offerings thereby advancing Thermo’s customers’ work, from discovery to diagnostics.

Thermo Fisher Scientific to acquire Qiagen

Specifically, the transaction will expand Thermo's specialty diagnostics portfolio with molecular diagnostics capabilities, including infectious disease testing.

Qiagen, which employs around 5,100 people at 35 locations in more than 25 countries, provides sample preparation technologies to extract, isolate and purify DNA, RNA and proteins from a wide range of biological samples.

The company's assay technologies are then used to amplify and enrich these biomolecules to make them readily accessible for analysis. In addition, the company's instruments can be used to automate these workflows, whereas its bioinformatics systems provide customers with relevant, actionable insights.

"This acquisition provides us with the opportunity to leverage our industry-leading capabilities and R&D expertise to accelerate innovation and address emerging healthcare needs,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific.

"This strategic step with Thermo Fisher ... is designed to deliver significant cash value to our shareholders, while enabling us to accelerate the expansion of our solutions to provide customers worldwide with breakthroughs that advance our knowledge about the science of life and improve health outcomes," said Thierry Bernard, interim chief executive officer of Qiagen and senior vice president, head of the molecular diagnostics business area.

Read More

Related news

New blood test able to detect 50 cancer types

New blood test able to detect 50 cancer types

31 Mar 2020

Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.

Read more 
European patent granted for amatoxin conjugates for tumor therapy

European patent granted for amatoxin conjugates for tumor therapy

31 Mar 2020

The patent covers the crosslinking of certain carrier molecules, for example, antibodies, via specific binding sites to amatoxins.

Read more 
ProBioGen selected for development and large-scale manufacturing services

ProBioGen selected for development and large-scale manufacturing services

24 Mar 2020

The Contract Development and Manufacturing Organization (CDMO) and technology provider will use its CHO.RiGHT expression platform for high-titer cell line development.

Read more 
Positive update on the development of new XF‐platform drug formulations

Positive update on the development of new XF‐platform drug formulations

24 Mar 2020

Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.

Read more 
Alvotech and DKSH partner to bring key biosimilar to Asia

Alvotech and DKSH partner to bring key biosimilar to Asia

24 Mar 2020

Together, the companies will provide APAC markets with a cost-effective alternative to the largest-selling blockbuster medicine worldwide.

Read more 
Codexis and Takeda collaborate to advance novel gene therapies

Codexis and Takeda collaborate to advance novel gene therapies

23 Mar 2020

Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies.

Read more 
Vaxxas HD-MAP to deliver vaccines directly to the skin

Vaxxas HD-MAP to deliver vaccines directly to the skin

17 Mar 2020

Company awarded US$5 million grant for clinical study of measles and rubella vaccination using Vaxxas’ high-density, micro-array patch.

Read more 
Regeneron and Sanofi begin global Kevzara clinical trial program in patients with severe COVID-19

Regeneron and Sanofi begin global Kevzara clinical trial program in patients with severe COVID-19

16 Mar 2020

The trial is the first controlled trial in the US to evaluate the effect of IL-6 inhibition prospectively in COVID-19 patients.

Read more 
Technique improves drug delivery system characterization

Technique improves drug delivery system characterization

16 Mar 2020

Postnova Analytics' CF2000 Centrifugal Field Flow Fractionation (CF3) system is delivering exciting new data to scientists developing drug delivery systems.

Read more 
Nanoform and Orion collaborate on 'nanoformed' APIs

Nanoform and Orion collaborate on 'nanoformed' APIs

9 Mar 2020

Active pharmaceutical ingredients (APIs) nanoformed using the CESS process demonstrate promise for overcoming solubility and bioavailability challenges.

Read more